Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation

Cancer Biology and Therapy

Volumn 12, Issue 9, 2011, Pages 788-796

  Davies, Kurtis D ^a   Cable, P LouAnn ^a   Garrus, Jennifer E ^a   Sullivan, Francis X ^a   Von Carlowitz, Ira ^a   Le Huerou, Yvan ^a   Wallace, Eli ^a   Woessner, Richard D ^a   Gross, Stefan ^a  

^a ARRAY BIOPHARMA INC   (United States)

Author keywords

Cell cycle; Chk1; Cyclin dependent kinase; DNA damage; DNA replication; Synergy; Wee1

Indexed keywords

ANTINEOPLASTIC AGENT; AR 458323; CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HISTONE H2AX; HISTONE H3; MK 1775; PHOSPHOTRANSFERASE; PROTEIN WEE1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE TARGETING; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA REPLICATION; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; RNA, SMALL INTERFERING;

EID: 80655141261     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.9.17673     Document Type: Article

References (47)

1. Tse AN, Rendahl KG, Sheikh T, Cheema H, Aardalen K, Embry M, et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res 2007; 13:591-602; PMID:17255282; DOI:10.1158/1078-0432.CCR-06-1424.
2. Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO, et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 2007; 6:104-10; PMID:17245119; DOI:10.4161/cc.6.1.3699.
3. Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther 2008; 7:2394-404; PMID:18723486; DOI:10.1158/1535-7163.MCT-07-2391.
4. Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ, et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 2009; 8:45-54; PMID:19139112; DOI:10.1158/1535-7163. MCT-08-0662.
5. Zhang C, Yan Z, Painter CL, Zhang Q, Chen E, Arango ME, et al. PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts. Clin Cancer Res 2009; 15:4630-40; PMID:19584159; DOI:10.1158/1078-0432.CCR-08-3272.
6. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010; 70:4972-81; PMID:20501833; DOI:10.1158/0008-5472.CAN- 09-3573.
7. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000; 14:1448-59; PMID:10859164.
8. Takai H, Tominaga K, Motoyama N, Minamishima YA, Nagahama H, Tsukiyama T, et al. Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev 2000; 14:1439-47; PMID:10859163.
9. Syljuåsen RG, Sorensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets and DNA breakage. Mol Cell Biol 2005; 25:3553-62; PMID:15831461; DOI:10.1128/MCB.25.9.3553-62.2005.
10. Petermann E, Caldecott KW. Evidence that the ATR/ Chk1 pathway maintains normal replication fork progression during unperturbed S phase. Cell Cycle 2006; 5:2203-9; PMID:16969104; DOI:10.4161/cc.5.19.3256.
11. Davies KD, Humphries MJ, Sullivan FX, von Carlowitz I, Le Huerou Y, Mohr PJ, et al. Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo. Oncol Res 2011; 19;349-63. DOI:10.3727/096504011X13079697132961
12. Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci USA 2011; 108:3336-41; PMID:21289283; DOI:10.1073/pnas.1012351108.
13. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 2010; 16:376-83; PMID:20068082; DOI:10.1158/1078-0432.CCR-09-1029.
14. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21; PMID:15829967; DOI:10.1038/nature03445.
15. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADPribose) polymerase. Nature 2005; 434:913-7; PMID:15829966; DOI:10.1038/nature03443.
16. Paternot S, Roger PP. Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation. Cancer Res 2009; 69:4577-81; PMID:19458076; DOI:10.1158/0008-5472.CAN-08-3260.
17. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008; 118:3051-64; PMID:18725989.
18. Furnari B, Rhind N, Russell P. Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase. Science 1997; 277:1495-7; PMID:9278510; DOI:10.1126/science.277.5331.1495.
19. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 1997; 277:1497-501; PMID:9278511; DOI:10.1126/science.277.5331.1497.
20. Parker LL, Piwnica-Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992; 257:1955-7; PMID:1384126; DOI:10.1126/science.1384126.
21. Stathis A, Oza A. Targeting Wee1-like protein kinase to treat cancer. Drug News Perspect 2010; 23:425-9; PMID:20862394.
22. Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009; 8:2992-3000; PMID:19887545; DOI:10.1158/1535-7163.MCT-09-0463.
23. Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010; 9:514-22; PMID:20107315; DOI:10.4161/cbt.9.7.11115.
24. Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters JW, Brooks D, Demuth T, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 2011; 17:2799-806.
25. Rodriguez R, Meuth M. Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell 2006; 17:402-12; PMID:16280359; DOI:10.1091/mbc.E05-07-0594.
26. Durkin SG, Arlt MF, Howlett NG, Glover TW. Depletion of CHK1, but not CHK2, induces chromosomal instability and breaks at common fragile sites. Oncogene 2006; 25:4381-8; PMID:16732333; DOI:10.1038/sj.onc.1209466.
27. Zachos G, Rainey MD, Gillespie DA. Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J 2003; 22:713-23; PMID:12554671; DOI:10.1093/emboj/cdg060.
28. Niida H, Tsuge S, Katsuno Y, Konishi A, Takeda N, Nakanishi M. Depletion of Chk1 leads to premature activation of Cdc2-cyclin B and mitotic catastrophe. J Biol Chem 2005; 280:39246-52; PMID:16159883; DOI:10.1074/jbc.M505009200.
29. Murrow LM, Garimella SV, Jones TL, Caplen NJ, Lipkowitz S. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat 2010; 122:347-57; PMID:19821025; DOI:10.1007/s10549-009-0571-2.
30. Yuan H, Xie YM, Chen IS. Depletion of Wee-1 kinase is necessary for both human immunodeficiency virus type 1 Vpr- and gamma irradiation-induced apoptosis. J Virol 2003; 77:2063-70; PMID:12525641; DOI:10.1128/JVI.77.3.2063- 70.2003.
31. Tominaga Y, Li C, Wang RH, Deng CX. Murine Wee1 plays a critical role in cell cycle regulation and preimplantation stages of embryonic development. Int J Biol Sci 2006; 2:161-70; PMID:16810330.
32. Beck H, Nahse V, Larsen MS, Groth P, Clancy T, Lees M, et al. Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase. J Cell Biol 2010; 188:629-38; PMID:20194642; DOI:10.1083/jcb.200905059.
33. Lam MH, Liu Q, Elledge SJ, Rosen JM. Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 2004; 6:45-59; PMID:15261141; DOI:10.1016/j.ccr.2004.06.015.
34. Cho SH, Toouli CD, Fujii GH, Crain C, Parry D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 2005; 4:131-9; PMID:15539958; DOI:10.4161/ cc.4.1.1299.
35. Chen CC, Kennedy RD, Sidi S, Look AT, D'Andrea A. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol Cancer 2009; 8:24; PMID:19371427; DOI:10.1186/1476-4598-8-24.
36. Leung-Pineda V, Ryan CE, Piwnica-Worms H. Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol 2006; 26:7529-38; PMID:17015476; DOI:10.1128/MCB.00447-06.
37. Gagou ME, Zuazua-Villar P, Meuth M. Enhanced H2AX phosphorylation, DNA replication fork arrest and cell death in the absence of Chk1. Mol Biol Cell 2010; 21:739-52; PMID:20053681; DOI:10.1091/mbc.E09-07-0618.
38. Niida H, Katsuno Y, Banerjee B, Hande MP, Nakanishi M. Specific role of Chk1 phosphorylations in cell survival and checkpoint activation. Mol Cell Biol 2007; 27:2572-81; PMID:17242188; DOI:10.1128/MCB.01611-06.
39. Hattori H, Skoulidis F, Russell P, Venkitaraman AR. Context Dependence of Checkpoint Kinase 1 as a Therapeutic Target for Pancreatic Cancers Deficient in the BRCA2 Tumor Suppressor. Mol Cancer Ther 2011; 10:670-8; PMID:21289082; DOI:10.1158/1535-7163.MCT-10-0781.
40. Mizuarai S, Yamanaka K, Itadani H, Arai T, Nishibata T, Hirai H, et al. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer 2009; 8:34; PMID:19500427; DOI:10.1186/1476-4598-8-34.
41. Wang Y, Decker SJ, Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 2004; 3:305-13; PMID:14726685; DOI:10.4161/cbt.3.3.697.
42. Sørensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J, et al. The cell cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005; 7:195-201; PMID:15665856; DOI:10.1038/ncb1212.
43. Zachos G, Black EJ, Walker M, Scott MT, Vagnarelli P, Earnshaw WC, et al. Chk1 is required for spindle checkpoint function. Dev Cell 2007; 12:247-60; PMID:17276342; DOI:10.1016/j.devcel.2007.01.003.
44. Wang X, Kennedy RD, Ray K, Stuckert P, Ellenberger T, D'Andrea AD. Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/ BRCA pathway. Mol Cell Biol 2007; 27:3098-108; PMID:17296736; DOI:10.1128/MCB.02357- 06.
45. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996; 88:956-65; PMID:8667426; DOI:10.1093/jnci/88.14.956.
46. Levesque AA, Fanous AA, Poh A, Eastman A. Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest. Mol Cancer Ther 2008; 7:252-62; PMID:18281511; DOI:10.1158/1535-7163. MCT-07-2066.
47. Cavelier C, Didier C, Prade N, Mansat-De Mas V, Manenti S, Recher C, et al. Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy. Cancer Res 2009; 69:8652-61; PMID:19843865; DOI:10.1158/0008-5472.CAN- 09-0939.